DELFICTUS IO — COMPUTATIONAL STRUCTURAL BIOLOGY INFRASTRUCTURE

PRISM-4D

Physics-driven cryptic and allosteric binding-site discovery.

An event-manifold engine. Reads recurrent nonequilibrium dynamics from a single static structure, surfacing pockets that conventional methods conceal. Validated end-to-end on a consumer-grade GPU; scales to multi-node and fully air-gapped cleanroom deployment.

Capability
Detect
Cryptic and allosteric pockets surfaced from recurrent nonequilibrium dynamics — not static geometry.
Profile
Per-site pocket chemistry, lining residues, anchor points, and growth vectors.
Triage
Hits reorganized into pocket-anchored series for series-level SAR exploration.
Rank
Lexicographic on persistence → pass-fraction → stability → quality. No composite scores.
Brief
DesignBrief output: site → anchors → growth vectors → pharmacophore. Medicinal-chemistry-ready.
Deploy
Consumer-GPU baseline (bioRxiv-validated) through multi-node scaling and air-gapped cleanroom deployment.
Workflow

PRISM-4D enters a hit-to-lead campaign at three distinct points and adds capability that conventional structure-based pipelines don't: target enablement before the screen, pocket-anchored triage after it, and detection of binding sites that static-structure methods miss entirely. End-to-end validation in the bioRxiv preprint runs on a single consumer-grade GPU — the democratization baseline for groups without HPC access — while the same engine supports multi-node scaling and fully air-gapped cleanroom deployment when campaign size or compliance posture requires it.

Pre-screen · Target enablement
Make undruggable targets tractable for the first compound
High-value targets — KRAS isoforms, mutant p53, tau filament, polyQ aggregators, transcription-factor interfaces — expose no obvious druggable pocket in their static structures. Conventional virtual screens against them either fail or return false positives at the orthosteric surface. PRISM-4D analyzes recurrent nonequilibrium dynamics and surfaces cryptic and allosteric pockets with measured persistence, lining residues, and accessibility profile. The output seeds a fresh fragment, virtual, or DEL screen against pockets conventional analyses rule out.
Post-screen · Triage
Pocket-anchored hit organization, not flat enrichment
Hit-to-lead bottlenecks at validation: hundreds of putative binders, limited assay capacity, no rational basis for prioritization beyond raw enrichment. PRISM-4D contributes pocket-level provenance — which hits share a cryptic pocket, which engage an allosteric site, which appear to bind a transient artifact surface. Hits reorganize into pocket-anchored series rather than a flat ranked list, shifting medicinal-chemistry triage from one-off compound assessment to series-level SAR exploration.
Detection
Reach pockets static methods cannot
On a 9-target prediction-locked blind panel: fpocket 22%, P2Rank 38%, PRISM-4D 48%. The additional 10–26 percentage points are cryptic pockets that static-geometry detectors do not recover. Null-control separation is p ≤ 0.001 against a temporal-scramble baseline, with 12.2× PFR enrichment over a permutation null on the same panel. The detection delta matters in programs where one missed pocket is the difference between a viable and a dead campaign.
Deployment · Air-gapped
Nothing leaves the facility
PRISM-4D deploys entirely inside the facility's network boundary — at the consumer-GPU democratization baseline validated in the bioRxiv preprint, at multi-node cluster scale when campaign size demands it, or in a fully isolated cleanroom configuration when compliance posture requires it. Target structures, hit libraries, ADMET tables, and proprietary annotation do not transit external infrastructure — no API calls out, no telemetry, no license-server callback. This is the deployment posture for IP-sensitive programs, sovereign or defense-adjacent research, regulated environments where SaaS uploads trigger compliance review, and any program where data residency is non-negotiable. Deployment surface is identical across the workstation, the multi-GPU rack, and the fully isolated cleanroom terminal: one binary, one driver, one local data store.
Explore

Five entry points into the platform — pick the one closest to your role and open the surface. Each card below is a clickable destination.

For researchers & academia
Read the preprint, retrieve the archive, run a public-tier scan.
The IO Hub aggregates the preprint, the Zenodo reproducibility deposit, and the public-tier hosted demo. Public-tier access is immediate and anonymous.
Open IO Hub
For engineers & scientists
Run the live engine on any of the preprint-validated targets.
Submit one target — or the full B01–B10 freeze scope — to the production PRISM-4D engine running on operator-side GPU infrastructure. Logs and ranked-pocket results stream back in real time. Tier 2 and 3 unlock deeper observability. Distinct from the PRISM-AI predictor demo (in development).
Open Live Engine
For translational biology & decision teams
Inspect the PRISM-DSTW bridge layer and manifold observatory.
PRISM-DSTW turns PRISM-4D physics into assay-facing evidence through typed bridge contracts, Bayesian calibration, active learning, and chronology-bound decision artifacts.
Open PRISM-DSTW
For reviewers & editors
Request reviewer-tier access for extended logs and curated targets.
Tier 2 access opens extended post-freeze logs, intermediate manifold artifacts, and additional curated targets beyond the public panel. Issued by request.
Request Access
For partners & counsel
Confidential review channel for licensing and counsel-supervised inspection.
Tier 3 engagement exposes engine internals, model weights, and raw execution artifacts under NDA. Coordinated through counsel; access is engagement-scoped.
Initiate Inquiry
bioRxiv MS BIORXIV/2026/725676 Zenodo DOI 10.5281/zenodo.20247900 USPTO Prov. 64/067,538 (2026-05-16) UEI LXT3B9GMY4N8 CAGE 13H70 Manifest SHA-256 73d178…5930